1,695 results on '"Anders, Hans-Joachim"'
Search Results
2. A new era in the science and care of kidney diseases
3. Präklinische randomisierte kontrollierte Studien in der Nephrologie
4. Toll-like receptors 2 and 4 stress signaling and sodium-glucose cotransporter-2 in kidney disease
5. Anti-slit diaphragm antibodies on kidney biopsy identify pediatric patients with steroid-resistant nephrotic syndrome responsive to second-line immunosuppressants
6. Gasdermin D drives focal crystalline thrombotic microangiopathy by accelerating immunothrombosis and necroinflammation
7. Glomerulonephritis: immunopathogenesis and immunotherapy
8. Lupus Nephritis: New and Emerging Biologic and Targeted Therapies
9. Balancing efficacy and safety of complement inhibitors
10. Molecular Pathomechanisms of Crystal-Induced Disorders
11. Auswirkungen von Lupus auf die Nieren
12. Targeting the Type I Interferon Pathway in Glomerular Kidney Disease: Rationale and Therapeutic Opportunities
13. Erythrocytosis and CKD: A Review
14. When should targeted therapies be used in the treatment of lupus nephritis: Early in the disease course or in refractory patients?
15. Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial
16. Expectations in children with glomerular diseases from SGLT2 inhibitors
17. From systemic lupus erythematosus to lupus nephritis: The evolving road to targeted therapies
18. Seltene glomeruläre Erkrankungen
19. Congenital Anomalies of the Kidney and Urinary Tract: A Continuum of Care
20. Both hyperglycemia and hyperuricemia aggravate acute kidney injury during cholesterol embolism syndrome despite opposite effects on kidney infarct size
21. Finerenone Added to RAS/SGLT2 Blockade for Chronic Kidney Disease in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice
22. Preclinical Randomized Controlled Trials in Nephrology
23. Pathogenesis: Hemodynamic Alterations
24. Abstract 13695: Finerenone Added to RAS/SGLT2 Blockade for Non-Diabetic Chronic Kidney Disease. Results of a Preclinical Double-Blinded Randomized Controlled Trial
25. Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3−/− Mice
26. Selective depletion of a CD64-expressing phagocyte subset mediates protection against toxic kidney injury and failure
27. Skeletal and extraskeletal disorders of biomineralization
28. Epigenetic regulation of Toll-like receptors 2 and 4 in kidney disease
29. Macrophages in Lupus Nephritis: Exploring a potential new therapeutic avenue
30. Soluble uric acid inhibits β2 integrin–mediated neutrophil recruitment in innate immunity
31. Nephron overload as a therapeutic target to maximize kidney lifespan
32. Tubular cell polyploidy protects from lethal acute kidney injury but promotes consequent chronic kidney disease
33. A Clinical Workflow for Cost-Saving High-Rate Diagnosis of Genetic Kidney Diseases
34. Gasdermin D-deficient mice are hypersensitive to acute kidney injury
35. #525 SGLT2 inhibition in non-diabetic CKD: results in experimental lupus nephritis
36. #439 Nephron number determination in whole slide mice kidney specimens using a deep learning assisted disector/fractionator approach
37. #921 Interferon regulatory factor 4 (IRF4)-specific deletion on dendritic cells protects against kidney inflammation and injury in IRI-induced AKI/AKD
38. #855 Cyclophilin D in cholesterol crystal-induced acute kidney injury
39. Immunosuppression Withdrawal in Patients with Lupus Nephritis
40. Erythrocytosis and CKD
41. Patients with COVID-19: in the dark-NETs of neutrophils
42. Klotho: A possible mechanism of action of SGLT2 inhibitors preventing episodes of acute kidney injury and cardiorenal complications of diabetes
43. From kidney injury to kidney cancer
44. A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Faslpr mice with proliferative lupus nephritis predicts low effect size
45. Contributors
46. Kidney—Inflammation and remodeling
47. Inhibition of complement factor C5a or C5aR for cholesterol crystal embolism–related vascular thrombosis with microvascular injury and its consequences
48. Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis et al
49. Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies.
50. Author Correction: Skeletal and extraskeletal disorders of biomineralization
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.